Parameters of ‘peroxidation — antioxidant defense’ system and platelet–derived growth factor level in endocrine ophthalmopathy in the course of glucocorticoid pulse therapy

Abstract

INTRODUCTION: Endocrine ophthalmopathy (EO) is a multifactorial autoimmune disease, with the need of further study of immunological and biochemical pathogenetic factors of this disease.

AIM: To assess the levels of thiobarbituric acid reactive substances (TBARS), total antioxidant activity, and the BB isoform of platelet–derived growth factor (PDGF-BB) in patients with EO in the course of glucocorticoid pulse therapy.

MATERIALS AND METHODS: A total of 30 individuals were examined, from which 2 groups were formed: a control group (n = 15) and a clinical group of patients with an active phase of EO before and after glucocorticoid pulse therapy (n = 15). A comparative clinical and laboratory analysis was conducted that included a comprehensive ophthalmological examination, determination of TBARS level, of the total antioxidant activity and PDGF-BB in blood serum.

RESULTS: TBARS concentration in the EO group before glucocorticoid pulse therapy exceeded values of the control group (р < 0.001) and did not differ from the parameters after treatment (р = 0.683). The total antioxidant activity before treatment was reduced compared to the control (р < 0.001) and also had no significant differences with the parameters after treatment (р = 0.345). The level of PDGF-BB in the active phase of EO before pulse therapy 2.3 times exceeded that of the control group (р < 0.001), 1.5 times decreased with pulse therapy (р < 0.001), but remained 1.6 times (р = 0.008) the control. Statistically significant relationships were found between the content of PDGF-BB and parameters of ‘peroxidation — antioxidant defense’ system (p < 0.001).

CONCLUSION: In patients with EO in the active phase, an imbalance in the ‘peroxidation — antioxidant defense’ system was found in terms of increased production of TBARS. In the course of glucocorticoid pulse therapy, the identified imbalance persisted. In the active phase of the disease, a significant increase in the level of PDGF-BB was detected, with the concentration remaining elevated after treatment. Correlations were established between the parameters of oxidative stress and the level of PDGF-BB. In view of the obtained data, it seems necessary to develop and introduce the alternative treatment methods for EO targeted at trigger points in the pathogenesis of this disease.

Keywords

endocrine ophthalmopathy / glucocorticoid pulse therapy / oxidative stress / total antioxidant activity / platelet–derived growth factor

References

[1] Zheng J, Duan H, You S, et al. Research progress on the patho-genesis of Graves' ophthalmopathy: Based on immunity, noncoding RNA and exosomes. Front Immunol. 2022;13:952954. doi: 10.3389/fimmu.2022.952954

[2] Zheng J., Duan H., You S., et al. Research progress on the pathogenesis of Graves' ophthalmopathy: Based on immunity, noncoding RNA and exosomes // Front. Immunol. 2022. Vol. 13. P. 952954. doi: 10.3389/fimmu.2022.952954

[3] Mishra S, Maurya VK, Kumar S, et al. Clinical management and therapeutic strategies for the Thyroid-Associated ophthalmopathy: current and future perspectives. Curr Eye Res. 2020;45(11):1325–41. doi: 10.1080/02713683.2020.1776331

[4] Mishra S., Maurya V.K., Kumar S., et al. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives // Curr. Eye Res. 2020. Vol. 45, No. 11. P. 1325–1341. doi: 10.1080/02713683.2020.1776331

[5] Hoang TD, Stocker DJ, Chou EL, et al. Update on Clinical Management of Graves Disease and Thyroid Eye Disease. Endocrinol Metab Clin North Am. 2022;51(2):287–304. doi: 10.1016/j.ecl.2021.12.004

[6] Hoang T.D., Stocker D.J., Chou E.L., et al. 2022 Update on clinical management of Graves Disease and Thyroid Eye Disease // Endocrinol. Metab. Clin. North Am. 2022. Vol. 51, No. 2. P. 287–304. doi: 10.1016/j.ecl.2021.12.004

[7] Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185(4):G43–67. doi: 10.1530/eje-21-0479

[8] Bartalena L., Kahaly G.J., Baldeschi L., et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy // Eur. J. Endocrinol. 2021. Vol. 185, No. 4. P. G43–G67. doi: 10.1530/eje-21-0479

[9] Längericht J, Krämer I, Kahaly GJ. Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application. Ther Adv Endocrinol Metab. 2020;11:2042018820958335. doi: 10.1177/2042018820958335

[10] Längericht J., Krämer I., Kahaly G.J. Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application // Ther. Adv. Endocrinol. Metab. 2020. Vol. 11. P. 2042018820958335. doi: 10.1177/2042018820958335

[11] Tregubova NV. The role of lipid peroxidation in inflammation. Newsletter of North-Caucasus Federal University. 2013;(2):101–5. (In Russ).

[12] Трегубова Н.В. Роль перекисного окисления липидов при воспалении // Вестник Северо-Кавказского федерального университета. 2013. № 2. С. 101–105.

[13] Ma C, Li H, Lu S, et al. Thyroid-associated ophthalmopathy: the role of oxidative stress. Front Endocrinol (Lausanne). 2024;15:1400869. doi: 10.3389/fendo.2024.1400869

[14] Ma C., Li H., Lu S., et al. Thyroid-associated ophthalmopathy: the role of oxidative stress // Front. Endocrinol. (Lausanne). 2024. Vol. 15. P. 1400869. doi: 10.3389/fendo.2024.1400869

[15] Hou T–Y, Wu S–B, Kau H–C, et al. The Role of Oxidative Stress and Therapeutic Potential of Antioxidants in Graves' Ophthalmopathy. Biomedicines. 2021;9(12):1871. doi: 10.3390/biomedicines9121871

[16] Hou T.–Y., Wu S.–B., Kau H.–C., et al. The Role of Oxidative Stress and Therapeutic Potential of Antioxidants in Graves' Ophthalmopathy // Biomedicines. 2021. Vol. 9, No. 12. P. 1871. doi: 10.3390/biomedicines9121871

[17] Papadopoulos N, Lennartsson J. The PDGF/PDGFR pathway as a drug target. Mol Aspects Med. 2018;62:75–88. doi: 10.1016/j.mam.2017.11.007

[18] Papadopoulos N., Lennartsson J. The PDGF/PDGFR pathway as a drug target // Mol. Aspects Med. 2018. Vol. 62. P. 75–88. doi: 10.1016/j.mam.2017.11.007

[19] Van Steensel L, Paridaens D, van Meurs M, et al. Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves' ophthalmopathy. J Clin Endocrinol Metab. 2012;97(3):E400–8. doi: 10.1210/jc.2011-2697

[20] Van Steensel L., Paridaens D., van Meurs M., et al. Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves' ophthalmo-pathy // J. Clin. Endocrinol. Metab. 2012. Vol. 97, No. 3. E400–E408. doi: 10.1210/jc.2011-2697

[21] Andrae J, Gallini R, Betsholtz C. Role of platelet–derived growth factors in physiology and medicine. Genes Dev. 2008;22(10):1276–312. doi: 10.1101/gad.1653708

[22] Andrae J., Gallini R., Betsholtz C. Role of platelet–derived growth factors in physiology and medicine // Genes Dev. 2008. Vol. 22, No. 10. P. 1276–1312. doi: 10.1101/gad.1653708

[23] Virakul S, Dalm VASH, Paridaens D, et al. Platelet–derived Growth Factor-BB Enhances Adipogenesis in Orbital Fibroblasts. Invest Ophthalmol Vis Sci. 2015;56(9):5457–64. doi: 10.1167/iovs.15-17001

[24] Virakul S., Dalm V.A.S.H., Paridaens D., et al. Platelet–derived Growth Factor-BB Enhances Adipogenesis in Orbital Fibroblasts // Invest. Ophthalmol. Vis. Sci. 2015. Vol. 56, No. 9. P. 5457–5464. doi: 10.1167/iovs.15-17001

[25] Lee J–Y, Yun M, Paik J–S, et al. PDGF-BB Enhances the Proliferation of Cells in Human Orbital Fibroblasts by Suppressing PDCD4 Expression Via Up-Regulation of microRNA-21. Invest Ophthalmol Vis Sci. 2016;57(3):908–13. doi: 10.1167/iovs.15-18157

[26] Lee J.–Y., Yun M., Paik J.–S., et al. PDGF-BB Enhances the Proliferation of Cells in Human Orbital Fibroblasts by Suppressing PDCD4 Expression Via Up-Regulation of microRNA-21 // Invest. Ophthalmol. Vis. Sci. 2016. Vol. 57, No. 3. P. 908–913. doi: 10.1167/iovs.15-18157

[27] Weiss MF, Scivittaro V, Anderson JM. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis. 2001;37(5):970–80. doi: 10.1016/s0272-6386(05)80013-7

[28] Weiss M.F., Scivittaro V., Anderson J.M. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access // Am. J. Kidney Dis. 2001. Vol. 37, No. 5. P. 970–980. doi: 10.1016/s0272-6386(05)80013-7

[29] Alekseyev VV, Alipov AN, Andreyev VA, et al.; Karpishchenko AI, editor. Meditsinskiye laboratornyye tekhnologii. Rukovodstvo po klinicheskoy i laboratornoy diagnostike. 3rd ed. Moscow: GEOTAR-Media; 2013. Vol. 2. (In Russ).

[30] Алексеев В.В., Алипов А.Н., Андреев В.А., и др.; Карпищенко А.И., ред. Медицинские лабораторные технологии. Руководство по клинической и лабораторной диагностике. 3-е изд. М.: ГЕОТАР-Медиа; 2013. Т. 2.

[31] Promyslov MSh, Demchuk ML. A modified method of determination of the total serum antioxidant activity. Vopr Med Khim. 1990;36(4):90–2. (In Russ).

[32] Промыслов М.Ш., Демчук М.Л. Модификация метода определения суммарной антиоксидантной активности сыворотки крови // Вопросы медицинской химии. 1990. Т. 36, № 4. С. 90–92.

[33] Taskina ES, Charinzeva SV. The role of interleukins 17, 23 and antibodies to the thyroid-stimulating hormone receptor in the pathogenesis of endocrine ophthalmopathy. Clinical and Experimental Thyroidology. 2018;14(2):72–80. (In Russ). doi: 10.14341/ket9703

[34] Таскина Е.С., Харинцева С.В. Значение интерлейкинов 17, 23 и антител к рецептору тиреотропного гормона в патогенезе эндокринной офтальмопатии // Клиническая и экспериментальная тиреоидология. 2018. Т. 14, № 2. С. 72–80. doi: 10.14341/ket9703

[35] Castaldo M, Zollo C, Esposito G, et al. NOX2-Dependent Reactive Oxygen Species Regulate Formyl-Peptide Receptor 1-Mediated TrkA Transactivation in SH-SY5Y Cells. Oxid Med Cell Longev. 2019;2019: 2051235. doi: 10.1155/2019/2051235

[36] Castaldo M., Zollo C., Esposito G., et al. NOX2-Dependent Reactive Oxygen Species Regulate Formyl-Peptide Receptor 1-Mediated TrkA Transactivation in SH-SY5Y Cells // Oxid. Med. Cell. Longev. 2019. Vol. 2019. P. 2051235. doi: 10.1155/2019/2051235

[37] Fan X, Wu J, Yang H, et al. Paeoniflorin blocks the proliferation of vascular smooth muscle cells induced by platelet–derived growth factor BB through ROS mediated ERK1/2 and p38 signaling pathways. Mol Med Rep. 2018;17(1):1676–82. doi: 10.3892/mmr.2017.8093

[38] Fan X., Wu J., Yang H., et al. Paeoniflorin blocks the proliferation of vascular smooth muscle cells induced by platelet–derived growth factor BB through ROS mediated ERK1/2 and p38 signaling pathways // Mol. Med. Rep. 2018. Vol. 17, No. 1. P. 1676–1682. doi: 10.3892/mmr.2017.8093

[39] Galgoczi E, Katko M, Papp FR, et al. Glucocorticoids Directly Affect Hyaluronan Production of Orbital Fibroblasts; A Potential Pleiotropic Effect in Graves' Orbitopathy. Molecules. 2022;28(1):15. doi: 10.3390/molecules28010015

[40] Galgoczi E., Katko M., Papp F.R., et al. Glucocorticoids Directly Affect Hyaluronan Production of Orbital Fibroblasts; A Potential Pleiotropic Effect in Graves' Orbitopathy // Molecules. 2022. Vol. 28, No. 1. P. 15. doi: 10.3390/molecules28010015

RIGHTS & PERMISSIONS

Eco-Vector